Document is current
Any future updates will be listed below
-
Authors
Huynh, Jasmine
Patel, Kanishka
Gong, Jun
Cho, May
Malla, Midhun
Parikh, Aparna
Klempner, Samuel https://orcid.org/0000-0002-4062-0808
-
Funding
Funding for this research was provided by:
AGA Research Foundation (AGA2020-13-02)
Stand Up To Cancer (Gastric Cancer Interception Award)
- License Information
-
More Information
Article History
Accepted: 1 July 2021
First Online: 15 September 2021
Declarations
:
: Jasmine Huynh declares that she has no conflict of interest. Kanishka Patel declares that she has no conflict of interest. Jun Gong has received compensation for service as a consultant from Exelixis, QED Therapeutics, Elsevier, Basilea, and HalioDx. May Cho has received compensation for service on advisory boards for Amgen, Eisai, Taiho, Astellas, Exelixis, Ipsen, Seagen, QED Therapeutics, AstraZeneca, Basilea, and Genentech/Roche, and serves on the speaker’s bureau for Pfizer and Taiho. Midhun Malla is supported, in part, by a grant from the NIH National Institute of General Medical Sciences (Grant #5U54GM104942-05); and has received compensation for service as a consultant/advisor from AstraZeneca, QED Therapeutics, Omni Health, and Curio Science. Aparna Parikh has received institutional research funding from PureTech Health, PMV Pharmaceuticals, Plexxikon, Takeda, Bristol-Myers Squibb, and Novartis; has received compensation for service as a consultant/advisor from Natera, Foundation Medicine, PureTech Health, Checkmate Pharmaceuticals, Eli Lilly, and Pfizer; serves on the DSMC for Roche; and holds equity in C2i Genomics. Samuel Klempner has received compensation for service as a consultant/advisor from Eli Lilly, Bristol-Myers Squibb, Merck, Astellas, Daiichi-Sankyo, Natera, and Pieris, and owns stock/equity in Turning Point Therapeutics.
: Not applicable.
: Not applicable.
: Not applicable.
